Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
David B PageHarry BearSangeetha PrabhakaranMargaret E Gatti-MaysAlexandra ThomasErin CobainHeather McArthurJustin M BalkoSofia R GameiroRita NandaJames L GulleyKevin KalinskyJulia WhiteJennifer LittonSteven J ChmuraMei-Yin PolleyBenjamin VincentDavid W CesconMary L DisisJoseph A SparanoElizabeth A MittendorfSylvia AdamsPublished in: NPJ breast cancer (2019)
Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.
Keyphrases
- metastatic breast cancer
- clinical practice
- end stage renal disease
- ejection fraction
- locally advanced
- newly diagnosed
- prognostic factors
- radiation therapy
- peritoneal dialysis
- electronic health record
- squamous cell carcinoma
- machine learning
- cell therapy
- combination therapy
- radiation induced
- climate change
- big data
- current status
- rectal cancer
- deep learning
- drug induced
- patient reported
- double blind